Urabrelimab
(Anti-human CD47 mAb, human IgG4 (S228P)-Kappa; SRF-231)
Catalog No.: PC-Ab1061Not For Human Use, Lab Use Only.
SRF-231 is fully human mAb for CD47, binds with high affinity to CD47, stimulates phagocytosis and the killing of cancer cells in vitro and has potent anti-tumor activity preclinically, both as monotherapy and in combination settings.disrupts the CD47/SIRPα interaction without causing hemagglutination or RBC phagocytosis. SRF231 exerts antitumor activity in vitro through both phagocytosis and cell death in a manner dependent on the activating Fc-gamma receptor (FcγR), CD32a. In tumor-bearing mic
Urabrelimab (SRF-231) is fully human mAb for CD47, binds with high affinity to CD47, stimulates phagocytosis and the killing of cancer cells in vitro and has potent anti-tumor activity preclinically, both as monotherapy and in combination settings.
Urabrelimab (SRF-231) disrupts the CD47/SIRPα interaction without causing hemagglutination or RBC phagocytosis.
Urabrelimab (SRF-231) exerts antitumor activity in vitro through both phagocytosis and cell death in a manner dependent on the activating Fc-gamma receptor (FcγR), CD32a.
In tumor-bearing mice, SRF231 increases tumor macrophage infiltration and induction of the macrophage cytokines, mouse chemoattractant protein 1 and macrophage inflammatory protein 1 alpha.
SRF231 is an investigational fully human IgG4 anti-CD47 antibody that is currently under evaluation in a phase 1 clinical trial.
Physicochemical Properties
M.Wt
Formula
Human IgG4 (S228P)-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
